154 related articles for article (PubMed ID: 10473022)
21. Safety of palivizumab in preterm infants 29 to 32 weeks' gestational age without chronic lung disease to prevent serious respiratory syncytial virus infection.
Groothuis JR
Eur J Clin Microbiol Infect Dis; 2003 Jul; 22(7):414-7. PubMed ID: 12827537
[TBL] [Abstract][Full Text] [Related]
22. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.
Carbonell-Estrany X
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of palivizumab prophylaxis in children with congenital heart disease.
Saji T; Nakazawa M; Harada K
Pediatr Int; 2005 Aug; 47(4):397-403. PubMed ID: 16091076
[TBL] [Abstract][Full Text] [Related]
24. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
25. [Prophylaxis of respiratory syncytial virus (RSV) in preterm infants with/without bronchopulmonary dysplasia: hyperimmune globulin (RSV-IGIV) and palivizumab (MEDI-493)].
Resch B; Müller W
Klin Padiatr; 1999; 211(6):450-5. PubMed ID: 10592925
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.
Cetinkaya M; Oral TK; Karatekin S; Cebeci B; Babayigit A; Yesil Y
Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1629-1634. PubMed ID: 28391538
[TBL] [Abstract][Full Text] [Related]
27. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
Wu H; Pfarr DS; Johnson S; Brewah YA; Woods RM; Patel NK; White WI; Young JF; Kiener PA
J Mol Biol; 2007 May; 368(3):652-65. PubMed ID: 17362988
[TBL] [Abstract][Full Text] [Related]
28. Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV.
Pollack P; Groothuis JR
J Infect Chemother; 2002 Sep; 8(3):201-6. PubMed ID: 12373481
[TBL] [Abstract][Full Text] [Related]
29. Prevention of respiratory syncytial virus infection among Puerto Rican infants.
Winchester L; García L; García I; Concepción CB
P R Health Sci J; 2002 Sep; 21(3):191-3. PubMed ID: 12243108
[TBL] [Abstract][Full Text] [Related]
30. Palivizumab: where to from here?
Georgescu G; Chemaly RF
Expert Opin Biol Ther; 2009 Jan; 9(1):139-47. PubMed ID: 19063700
[TBL] [Abstract][Full Text] [Related]
31. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.
Blanken MO; Rovers MM; Molenaar JM; Winkler-Seinstra PL; Meijer A; Kimpen JL; Bont L;
N Engl J Med; 2013 May; 368(19):1791-9. PubMed ID: 23656644
[TBL] [Abstract][Full Text] [Related]
32. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.
Resch B
Hum Vaccin Immunother; 2017 Sep; 13(9):2138-2149. PubMed ID: 28605249
[TBL] [Abstract][Full Text] [Related]
33. Use of palivizumab to control an outbreak of syncytial respiratory virus in a neonatal intensive care unit.
Abadesso C; Almeida HI; Virella D; Carreiro MH; Machado MC
J Hosp Infect; 2004 Sep; 58(1):38-41. PubMed ID: 15350712
[TBL] [Abstract][Full Text] [Related]
34. Palivizumab: new indication. Moderate reduction in hospitalisation rate.
Prescrire Int; 2004 Dec; 13(74):213-6. PubMed ID: 15612142
[TBL] [Abstract][Full Text] [Related]
35. Palivizumab in prevention of bronchiolitis: new preparation. Moderate efficacy in some infants.
Prescrire Int; 2000 Dec; 9(50):171-2, 174. PubMed ID: 11475494
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection.
Lacaze-Masmonteil T; Seidenberg J; Mitchell I; Cossey V; Cihar M; Csader M; Baarsma R; Valido M; Pollack PF; Groothuis JR;
Drug Saf; 2003; 26(4):283-91. PubMed ID: 12608889
[TBL] [Abstract][Full Text] [Related]
37. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
Singleton R; Dooley L; Bruden D; Raelson S; Butler JC
Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
[TBL] [Abstract][Full Text] [Related]
38. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants.
Boeckh M; Berrey MM; Bowden RA; Crawford SW; Balsley J; Corey L
J Infect Dis; 2001 Aug; 184(3):350-4. PubMed ID: 11443562
[TBL] [Abstract][Full Text] [Related]
39. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection.
Sáez-Llorens X; Moreno MT; Ramilo O; Sánchez PJ; Top FH; Connor EM;
Pediatr Infect Dis J; 2004 Aug; 23(8):707-12. PubMed ID: 15295219
[TBL] [Abstract][Full Text] [Related]
40. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab.
Mitchell I; Tough S; Gillis L; Majaesic C
Pediatr Pulmonol; 2006 Dec; 41(12):1167-74. PubMed ID: 17058279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
